Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Spokane, WA, 99210, USA.
Adv Mater. 2018 May;30(22):e1706245. doi: 10.1002/adma.201706245. Epub 2018 Mar 26.
White blood cells (WBCs) are a major component of immunity in response to pathogen invasion. Neutrophils are the most abundant WBCs in humans, playing a central role in acute inflammation induced by pathogens. Adhesion to vasculature and tissue infiltration of neutrophils are key processes in acute inflammation. Many inflammatory/autoimmune disorders and cancer therapies have been found to be involved in activation and tissue infiltration of neutrophils. A promising strategy to develop novel targeted drug delivery systems is the targeting and exploitation of activated neutrophils. Herein, a new drug delivery platform based on neutrophils is reviewed. There are two types of drug delivery systems: neutrophils as carriers and neutrophil-membrane-derived nanovesicles. It is discussed how nanoparticles hijack neutrophils in vivo to deliver therapeutics across blood vessel barriers and how neutrophil-membrane-derived nanovesicles target inflamed vasculature. Finally, the potential applications of neutrophil-based drug delivery systems in treating inflammation and cancers are presented.
白细胞（WBCs）是机体针对病原体入侵的主要免疫成分。中性粒细胞是人类白细胞中最丰富的细胞，在病原体引起的急性炎症中发挥核心作用。中性粒细胞与血管的黏附和组织浸润是急性炎症的关键过程。许多炎症/自身免疫性疾病和癌症治疗方法已被发现与中性粒细胞的激活和组织浸润有关。开发新型靶向药物递送系统的一个有前途的策略是靶向和利用激活的中性粒细胞。本文综述了一种基于中性粒细胞的新型药物递送平台。有两种类型的药物递送系统：中性粒细胞作为载体和中性粒细胞膜衍生的纳米囊泡。本文讨论了纳米颗粒如何在体内劫持中性粒细胞，以穿过血管屏障递送来治疗药物，以及中性粒细胞膜衍生的纳米囊泡如何靶向炎症血管。最后，介绍了基于中性粒细胞的药物递送系统在治疗炎症和癌症方面的潜在应用。
